WO2022253935 - COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA
National phase entry:
Publication Number
WO/2022/253935
Publication Date
08.12.2022
International Application No.
PCT/EP2022/064993
International Filing Date
02.06.2022
Title **
[English]
COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA
[French]
COMPOSÉS POUR LE TRAITEMENT DU GLIOBLASTOME
Applicants **
MERCK PATENT GMBH
Inventors
GANN, Claudia-Nanette
CELIK, Ilhan
MAJD, Nazanin
DE GROOT, John Frederick
WELLER, Michael
Priority Data
63/197,163
04.06.2021
US
63/251,945
04.10.2021
US
63/278,789
12.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2341 | |
| EPO | Filing, Examination, Granting | 9503 | |
| Japan | Filing, Examination, Granting | 2215 | |
| South Korea | Filing, Examination, Granting | 2267 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,066
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention encompasses cMET inhibitors for use in the treatment of glioblastoma, including disseminated glioblastoma harboring MET amplification.[French]
La présente invention concerne des inhibiteurs de cMET destinés à être utilisés dans le traitement du glioblastome, y compris le glioblastome disséminé hébergeant l'amplification MET.